Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Operating Expenses data on file, last reported at $14.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $14.9 million, up 88.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.6 million (up 125.6% YoY), and the FY2025 annual result was $38.6 million, up 173.87% from the prior year.
• Operating Expenses grew to $14.9 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $31.3 million in Q3 2023 and troughed at -$54.9 million in Q4 2023.
• A 5-year average of $8.2 million and a median of $10.7 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 89.92% in 2024, then surged 347.47% in 2025.
• A 5-year view of Operating Expenses shows it stood at $17.5 million in 2022, then slumped by 413.02% to -$54.9 million in 2023, then soared by 107.95% to $4.4 million in 2024, then soared by 158.91% to $11.3 million in 2025, then surged by 31.41% to $14.9 million in 2026.
• Business Quant data shows PVLA's Operating Expenses at $14.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.2 million in Q3 2025.